Overexpression of CYP3A4, but not of CYP2D6, promotes hypoxic response and cell growth of Hep3B cells

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 4, 2011, Pages 407-415

  Oguro, Ami ^a   Sakamoto, Koichi ^a   Funae, Yoshihiko ^b   Imaoka, Susumu ^a  

^a KWANSEI GAKUIN UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell proliferation; Cytochrome P450 (CYP) 3A4; Human hepatocarcinoma cell; Hypoxia; Vascular endothelial growth factor (VEGF)

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; KETOCONAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; QUINIDINE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME INHIBITION; ERYTHROPOIETIN GENE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 80052594965     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-017     Document Type: Article

References (56)

1. Guengerich, F. P. and Shimada, T.: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol., 4: 391-407 (1991).
2. Gonzalez, F. J. and Gelboin, H. V.: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev., 26: 165-183 (1994).
3. Spector, A. A.: Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res., 50 Suppl: S52-S56 (2009).
4. Zhang, Y. Y. and Yang, L.: Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications. Expert Opin. Drug Metab. Toxicol., 5: 621-629 (2009).
5. Gervasini, G., Carrillo, J. A. and Benitez, J.: Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin. Pharmacokinet., 43: 693-706 (2004).
6. Zanger, U. M., Raimundo, S. and Eichelbaum, M.: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol., 369: 23-37 (2004).
7. Bertilsson, L., Dahl, M. L., Dalen, P. and Al-Shurbaji, A.: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol., 53: 111-122 (2002).
8. Snider, N. T., Sikora, M. J., Sridar, C., Feuerstein, T. J., Rae, J. M. and Hollenberg, P. F.: The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J. Pharmacol. Exp. Ther., 327: 538-545 (2008).
9. Zhou, S. F.: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 9: 310-322 (2008).
10. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
11. Windmill, K. F., McKinnon, R. A., Zhu, X., Gaedigk, A., Grant, D. M. and McManus, M. E.: The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat. Res., 376: 153-160 (1997).
12. Dhaini, H. R., Thomas, D. G., Giordano, T. J., Johnson, T. D., Biermann, J. S., Leu, K., Hollenberg, P. F. and Baker, L. H.: Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J. Clin. Oncol., 21: 2481-2485 (2003).
13. Kapucuoglu, N., Coban, T., Raunio, H., Pelkonen, O., Edwards, R. J., Boobis, A. R. and Iscan, M.: Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett., 202: 17-23 (2003).
14. Murray, G. I., Taylor, M. C., Burke, M. D. and Melvin, W. T.: Enhanced expression of cytochrome P450 in stomach cancer. Br. J. Cancer, 77: 1040-1044 (1998).
15. Keshava, C., McCanlies, E. C. and Weston, A.: CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am. J. Epidemiol., 160: 825-841 (2004).
16. Chen, Y., Tang, Y., Chen, S. and Nie, D.: Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol. Ther., 8: 1265-1272 (2009).
17. Yasuda, K., Ranade, A., Venkataramanan, R., Strom, S., Chupka, J., Ekins, S., Schuetz, E. and Bachmann, K.: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab. Dispos., 36: 1689-1697 (2008).
18. Pfrunder, A., Gutmann, H., Beglinger, C. and Drewe, J.: Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1- MRP5) and hPXR in three different human colon carcinoma cell lines. J. Pharm. Pharmacol., 55: 59-66 (2003).
19. Ayajiki, K., Fujioka, H., Toda, N., Okada, S., Minamiyama, Y., Imaoka, S., Funae, Y., Watanabe, S., Nakamura, A. and Okamura, T.: Mediation of arachidonic acid metabolite(s) produced by endothelial cytochrome P-450 3A4 in monkey arterial relaxation. Hypertens. Res., 26: 237-243 (2003).
20. Daikh, B. E., Lasker, J. M., Raucy, J. L. and Koop, D. R.: Regioand stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther., 271: 1427-1433 (1994).
21. Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R. and Zeldin, D. C.: Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem., 271: 3460-3468 (1996).
22. Campbell, W. B., Gebremedhin, D., Pratt, P. F. and Harder, D. R.: Identification of epoxyeicosatrienoic acids as endotheliumderived hyperpolarizing factors. Circ. Res., 78: 415-423 (1996).
23. Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D. R., Fleming, I. and Busse, R.: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 401: 493-497 (1999).
24. Spector, A. A. and Norris, A. W.: Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell Physiol., 292: C996-C1012 (2007).
25. Pozzi, A., Popescu, V., Yang, S., Mei, S., Shi, M., Puolitaival, S. M., Caprioli, R. M. and Capdevila, J. H.: The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J. Biol. Chem., 285: 12840-12850 (2010).
26. Jiang, J. G., Chen, C. L., Card, J. W., Yang, S., Chen, J. X., Fu, X. N., Ning, Y. G., Xiao, X., Zeldin, D. C. and Wang, D. W.: Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res., 65: 4707-4715 (2005).
27. Jiang, J. G., Ning, Y. G., Chen, C., Ma, D., Liu, Z. J., Yang, S., Zhou, J., Xiao, X., Zhang, X. A., Edin, M. L., Card, J. W., Wang, J., Zeldin, D. C. and Wang, D. W.: Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res., 67: 6665-6674 (2007).
28. Folkman, J.: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186 (1971).
29. Rey, S. and Semenza, G. L.: Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc. Res., 86: 236-242 (2010).
30. Suzuki, S., Oguro, A., Osada-Oka, M., Funae, Y. and Imaoka, S.: Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J. Pharmacol. Sci., 108: 79-88 (2008).
31. Oguro, A., Sakamoto, K., Suzuki, S. and Imaoka, S.: Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth. Biol. Pharm. Bull., 32: 1962-1967 (2009).
32. Božina, N., Bradamante, V. and Lovric, M.: Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh. Hig. Rada Toksikol., 60: 217-242 (2009).
33. Imaoka, S., Yamada, T., Hiroi, T., Hayashi, K., Sakaki, T., Yabusaki, Y. and Funae, Y.: Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem. Pharmacol., 51: 1041-1050 (1996).
34. Oguro, A., Fujita, N. and Imaoka, S.: Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression. Drug Metab. Pharmacokinet., 24: 438-445 (2009).
35. Osada, M., Imaoka, S., Sugimoto, T., Hiroi, T. and Funae, Y.: NADPH-cytochrome P-450 reductase in the plasma membrane modulates the activation of hypoxia-inducible factor 1. J. Biol. Chem., 277: 23367-23373 (2002).
36. Yasui, H., Hayashi, S. and Sakurai, H.: Possible involvement of singlet oxygen species as multiple oxidants in p450 catalytic reactions. Drug Metab. Pharmacokinet., 20: 1-13 (2005).
37. Liu, Y., Zhang, Y., Schmelzer, K., Lee, T. S., Fang, X., Zhu, Y., Spector, A. A., Gill, S., Morisseau, C., Hammock, B. D. and Shyy, J. Y.: The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA, 102: 16747-16752 (2005).
38. Wang, D. and Dubois, R. N.: Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res., 2008: 931074 (2008).
39. Potente, M., Fisslthaler, B., Busse, R. and Fleming, I.: 11,12- Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27kip1. J. Biol. Chem., 278: 29619-29625 (2003).
40. Pozzi, A., Macias-Perez, I., Abair, T., Wei, S., Su, Y., Zent, R., Falck, J. R. and Capdevila, J. H.: Characterization of 5,6- and 8,9- epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem., 280: 27138-27146 (2005).
41. Zhang, B., Cao, H. and Rao, G. N.: Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J. Biol. Chem., 281: 905-914 (2006).
42. Dhanasekaran, A., Gruenloh, S. K., Buonaccorsi, J. N., Zhang, R., Gross, G. J., Falck, J. R., Patel, P. K., Jacobs, E. R. and Medhora, M.: Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol., 294: H724-H735 (2008).
43. Chaudhary, K. R., Batchu, S. N., Das, D., Suresh, M. R., Falck, J. R., Graves, J. P., Zeldin, D. C. and Seubert, J. M.: Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovasc. Res., 83: 362-370 (2009).
44. Bodiga, S., Zhang, R., Jacobs, D. E., Larsen, B. T., Tampo, A., Manthati, V. L., Kwok, W. M., Zeldin, D. C., Falck, J. R., Gutterman, D. D., Jacobs, E. R. and Medhora, M. M.: Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. J. Mol. Cell. Cardiol., 46: 978-988 (2009).
45. Arnold, R. S., Shi, J., Murad, E., Whalen, A. M., Sun, C. Q., Polavarapu, R., Parthasarathy, S., Petros, J. A. and Lambeth, J. D.: Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc. Natl. Acad. Sci. USA, 98: 5550-5555 (2001).
46. Suh, Y. A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K. and Lambeth, J. D.: Cell transformation by the superoxide-generating oxidase Mox1. Nature, 401: 79-82 (1999).
47. Arbiser, J. L., Petros, J., Klafter, R., Govindajaran, B., McLaughlin, E. R., Brown, L. F., Cohen, C., Moses, M., Kilroy, S., Arnold, R. S. and Lambeth, J. D.: Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. USA, 99: 715-720 (2002).
48. Fleming, I., Michaelis, U. R., Bredenkotter, D., Fisslthaler, B., Dehghani, F., Brandes, R. P. and Busse, R.: Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res., 88: 44-51 (2001).
49. Lee, A. J., Cai, M. X., Thomas, P. E., Conney, A. H. and Zhu, B. T.: Characterization of the oxidative metabolites of 17betaestradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology, 144: 3382-3398 (2003).
50. Lee, A. J., Kosh, J. W., Conney, A. H. and Zhu, B. T.: Characterization of the NADPH-dependent metabolism of 17betaestradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J. Pharmacol. Exp. Ther., 298: 420-432 (2001).
51. Gao, N., Nester, R. A. and Sarkar, M. A.: 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol. Appl. Pharmacol., 196: 124-135 (2004).
52. Mitra, R., Guo, Z., Milani, M., Mesaros, C., Rodriguez, M., Nguyen, J., Luo, X., Clarke, D., Lamba, J., Schuetz, E., Donner, D. B., Puli, N., Falck, J. R., Capdevila, J., Gupta, K., Blair, I. A. and Potter, D. A.: CYP3A4 mediates growth of ER+ breast cancer cells, in part, by nuclear translocation of phospho-Stat3 through biosynthesis of (+)-14,15-EET. J. Biol. Chem. (2011).
53. Gingras, A. C., Raught, B. and Sonenberg, N.: mTOR signaling to translation. Curr. Top. Microbiol. Immunol., 279: 169-197 (2004).
54. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W. and Semenza, G. L.: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545 (2000).
55. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T. and Vogt, P. K.: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ., 12: 363-369 (2001).
56. Ikezoe, T., Hisatake, Y., Takeuchi, T., Ohtsuki, Y., Yang, Y., Said, J. W., Taguchi, H. and Koeffler, H. P.: HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res., 64: 7426-7431 (2004).